Development of CRB1 gene therapy using organosilica nanoparticle carriers for cervical cancer

2022 Fiscal Year Final Research Report

• Project/Area Number: 20K09601
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 56040:Obstetrics and gynecology-related
• Research Institution: Yamaguchi University
• Principal Investigator: Sueoka Kotaro 山口大学, 医学部附属病院, 准教授 (40452643)
• Project Period (FY): 2020-04-01 – 2023-03-31
• Keywords: 子宮頚癌 / CBR1 / 遺伝子治療用キャリア

Outline of Final Research Achievements

We hypothesized that CBR1 could be a useful therapeutic agent for cervical cancer. We investigated the development of a new gene therapy for cervical cancer using organosilica theranostics nano-carrier, which have multifunctional properties different from conventional nanoparticles, as carriers for gene therapy. (1) We were able to confirm that about 300 ng of plasmid DNA was added to OS/TNC by the addition reaction of plasmid DNA to OS/TNC. (2)Transfection of CBR1-OS/TNC into cancer cells was verified using the uterine cancer cell line SNGM. Although gene transfer was confirmed, we were unable to generate a model of overexpression at the protein and mRNA levels.
The results showed that expression of CBR1-OS/TNC did not cause overexpression of the transgene. On the other hand, the high transfection rate and safety/stability of OS/TNC may make OS/TNC a useful tool for tracking transplanted cells over time as a biological staining marker.

Free Research Field

子宮頚癌

Academic Significance and Societal Importance of the Research Achievements

OS/TNCの高いトランスフェクション率と安全性・安定性は、生体染色マーカーとして移植細胞を経時的に追跡する有用なツールになると考えられる。OS/TNCは、生物学的染色マーカーとして移植された細胞を経時的に追跡するための有用なツールになり得る。